Anti-Beta (β)-Amyloid antibody

Amyloids are insoluble protein aggregates consisting of misfolded proteins and peptides. Amyloid deposition are associated with multiple neurodegenerative disorders.

The β-amyloid precursor protein (APP) is cleaved sequentially by the proteolytic enzymes β-secretase (BACE1) and γ-secretase to produce β-amyloid (Aβ) peptides with the Aβ1-42 and the Aβ1-40 forms being the most prevalent. Secreted Aβ peptides are degraded either via a re-uptake mechanism followed by endosomal degradation, or by an extracellular insulin degrading enzyme. Extracellular accumulation of Aβ leads to the formation of aggregates, fibrils and eventually amyloid deposits called neuritic plaques, which is the hallmark of Alzheimer′s disease (AD).
Monoclonal Anti β-Amyloid [13-28] recognizes the β-Amyloid peptide. The antibody epitope resides within amino acids 20-23.

Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Immunohistochemistry (1 paper)

Mouse Monoclonal Anti-β-Amyloid (13-28) antibody can be used for immunoblotting assays at 1:5,000. The antibody can also be used for IHC, immunoprecipitation,fluorescence infrared spectroscopy and enzyme immunoassays (02-0.4μg/ml).

Filtered solution in 0.01 M phosphate buffered saline, pH 7.4.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.